EUVIMED · CrossrefJournal
European Heart Journal - Cardiovascular Pharmacotherapy
ISSN 2055-6837 · Oxford University Press (OUP)
Latest articles
From European Evidence to Asian Practice: Heart Failure and Precision Antithrombotic Therapy at GW-ICC/AHS 2026
Four drugs, fewer pills, better outcomes? Interpreting real-world evidence in complex hypertension
Beta-blocker therapy and angina burden after myocardial infarction: A prespecified substudy of the BETAMI-DANBLOCK trial
Statin–Ezetimibe Therapy and Incident Myocardial Infarction Across Modified Cardiovascular–Kidney–Metabolic Risk Groups: A Nationwide Target Trial Emulation
Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial
PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease
Authors’ reply to: ‘Stent-free is not risk-free: risk-defined DAPT after DCB-only PCI in ACS’
Reply to Erre et al: translating cardio-rheumatology into practice: a multi-level pilot network
Eplerenone vs. spironolactone in heart failure: long-term cardiorenal and mortality outcomes in a registry-based cohort
Comparative biomarker efficacy of cholesteryl ester transfer protein inhibitors: a network meta-analysis
Translating cardiorheumatology into practice: a multilevel pilot network
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
Vagal activity-related events and glucagon-like peptide-1 receptor agonists
Switching to angiotensin receptor–neprilysin inhibitor and reduced risk of new-onset atrial fibrillation in heart failure with reduced ejection fraction: a nationwide propensity score–matched study
Rewriting heart health: epigenetic drugs in cardiovascular medicine
Antiemetic-associated QT prolongation: a clinical review and risk-stratified prescribing framework for long QT syndrome
From digital reminders to artificial intelligence–enabled understanding: can personalized treatment predictions improve therapeutic adherence?
Can ARNI prevent atrial fibrillation in heart failure with reduced ejection fraction? Real-world evidence meets the randomized benchmark
Advancing and implementing cardiovascular drug therapy
When randomization is not enough: divergent β-blocker trials and the illusion of universal causality
Real-world analysis of adherence, persistence, and outcomes in patients receiving four-drug antihypertensive therapy
From stabilization to silencing in transthyretin amyloid cardiomyopathy: why sequencing should be treat-to-trajectory, not ‘one-and-done’
Management of dyslipidaemia in patients with comorbidities—facing the challenge: heart failure
Beta-blockers after myocardial infarction: indication, ejection fraction, and de-escalation pathway
Reply to Zhang and Lou: beta-blockers after myocardial infarction should be guided by indication, ejection fraction, and contemporary evidence
Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery: a proof-of-concept study
Longitudinal loop diuretic use in patients with HFrEF initiated with sodium–glucose cotransporter 2 inhibitors
Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation
Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation
Why cardio-rheumatology?
EUVIMED